As the United States continues to be a major market for India's pharmaceutical industry, experts in India are looking forward to new opportunities for collaboration in healthcare security and affordability with the new US administration under President Donald Trump. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, highlighted the growing relationship between India and the US, emphasizing the potential for cooperation in healthcare.
Jain noted the importance of building a resilient and diversified pharmaceutical supply chain. India has already implemented the Production Linked Incentive Scheme for active pharmaceutical ingredients, showing promising early results. A joint effort from both countries could accelerate this initiative, enhancing self-reliance and healthcare security. India plays a crucial role as a supplier of quality-assured medicines to the US and the global market.
Jain also mentioned the potential for exploring more opportunities in pharmaceutical research, development, and manufacturing. He believes healthcare can be a cornerstone of the partnership, helping to address common challenges like supply chain resilience and security.
Kiran Mazumdar, Chairperson of Biocon, expressed confidence in India's ability to meet global medical demands. She stated that India has established itself as a reliable supplier of essential medicines and can lead in manufacturing and exporting generic medicines to fill unmet medical needs.
The pharmaceutical industry is a part of the economy that makes and sells medicines and drugs. In India, this industry is very important because it produces a lot of the world's medicines.
Collaboration means working together. In this context, it means that India and the US are looking for ways to work together in healthcare and medicine.
Donald Trump was the President of the United States from 2017 to 2021. During his time, he made some changes in policies that affected how countries like India could work with the US.
Healthcare security means making sure that people have access to the medical care and medicines they need. It involves protecting the health of people by ensuring they can get treatment when they need it.
Affordability means how much something costs and whether people can pay for it. In healthcare, it means making sure medicines and treatments are not too expensive for people to buy.
Sudarshan Jain is a leader in the Indian pharmaceutical industry. He is part of the Indian Pharmaceutical Alliance, which is a group that represents the interests of Indian drug companies.
The Indian Pharmaceutical Alliance is a group of major pharmaceutical companies in India. They work together to promote the interests of the Indian pharmaceutical industry.
A resilient pharma supply chain means a strong and reliable system for making and delivering medicines. It ensures that medicines are available even during difficult times, like a pandemic.
Research and development, often called R&D, is the process of creating new products or improving existing ones. In pharmaceuticals, it involves discovering new medicines and making them better.
Biocon is a big Indian company that makes medicines. It is known for producing affordable and high-quality drugs, especially for diseases like diabetes and cancer.
Kiran Mazumdar is the founder of Biocon. She is a well-known businesswoman in India and has played a big role in making Biocon a successful pharmaceutical company.
Essential medicines are drugs that are needed to treat common health problems. They are considered necessary for a basic healthcare system and should be available to everyone.
Your email address will not be published. Required fields are marked *